Simon Jose

LETTER FROM SIMON JOSE

As President of Stiefel, a GSK company, I am looking forward to starting my tenure during this exciting time in the organization’s history and to reinforcing our commitment to physicians, patients and customers. I intend to work with the Stiefel team to ensure that we continue to advance the science of dermatology and deliver products that improve the skin health experience.

It has been three years since GlaxoSmithKline’s acquisition of Stiefel. During that time, you likely noticed considerable activity as our global business model evolved to meet the needs of patients and customers through a focus on science, innovation and our core values. As that business evolution continues, we are keen to take Stiefel forward to the next phase in its long and successful history.

I am aware that the dermatology field is hungry for new products to address unmet medical needs and is very eager to continuously improve existing products. The benefit of GSK’s acquisition of Stiefel is that we can now combine Stiefel’s deep, comprehensive knowledge and understanding of the science of dermatology with GSK’s resources. This combination creates a tremendous advantage with immense potential for the development and delivery of new products. I am particularly excited about Stiefel’s ability to tap into the potential of GSK’s extensive molecule library, and I see great opportunity to explore how we can maximize those assets on behalf of patients with skin conditions. We also are able to partner with a number of business units across GSK like Immuno-Inflammation, Oncology, Respiratory and Rare Diseases to deliver the best possible outcomes.

At the very heart of Stiefel, our values guide our actions. By focusing on patients, operating with integrity and transparency, and respecting customers, patients and each other, we are confident we can maintain your trust and meet your expectations.

In many cases, your primary interface with Stiefel is through our sales professionals and we continue to invest heavily in training and education so they have the knowledge, skills and patient focus to provide you with reliable information you can trust to make appropriate treatment decisions for your patients.

Our commitment to you and to patients is real and it is as strong as it has ever been. I am delighted to lead the Stiefel organization and look forward to developing and continuing a relationship with you.

Kind Regards,

Simon Jose

President, Stiefel, a GSK company